Panelists discuss how the pathophysiology of acute myeloid leukemia has evolved from a single phenotype understanding to recognizing diverse genetic events that lead to transformation at the ...

Panelists discuss how the treatment landscape has evolved from limited options to include hypomethylating agents and venetoclax combinations, with emerging oral formulations promising greater ...

Despite improved outcomes in newly diagnosed pediatric AML, relapsed disease remains a therapeutic challenge. Factors contributing to slow progress in improving outcomes include inherent challenges in ...

Moleculin Biotech ( (MBRX)) just unveiled an announcement. Moleculin Biotech has revealed promising findings showcasing Annamycin’s potential to combat acute myeloid leukemia (AML) resistant to ...

Relapsed acute myeloid leukemia (AML) is when cancer returns after a period of remission. Refractory AML means cancer has not responded to multiple rounds of treatment. Both can affect your treatment ...

Acute myeloid leukemia (AML) is a cancer of the bone marrow and the blood that progresses rapidly without treatment. The National Cancer Institute estimates 20,800 new cases of AML will be diagnosed ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. Given the biological complexity of acute ...

Ligufalimab targets CD47, enhancing macrophage-mediated cancer cell destruction, and avoids red blood cell clumping, improving safety and efficacy. Early trials show ligufalimab, combined with Vidaza ...

Aptose Biosciences Inc. has announced the initiation of patient dosing in its TUSCANY Phase 1/2 study, which is investigating a new triplet therapy combining tuspetinib, venetoclax, and azacitidine ...

Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated AML – – $2.1 million ...

Researchers at Oregon Health and Science University (OHSU) have discovered a promising new drug combination that could significantly improve treatment for people with acute myeloid leukemia (AML), one ...